Mike Zurawski joined KELES in December 2024 as Investment Partner and is based in London (UK). He is part of the KELES investment committee, works with the investment team building and reviewing dealflow as well as supporting portfolio companies on their growth trajectory and establishing strategic partnerships throughout the ecosystem.
Mike is driven by a deep commitment to revolutionizing patient access to cutting-edge healthcare technologies, enhancing outcomes, and fostering an inclusive, dynamic healthcare ecosystem that meets the needs of today’s diverse societies. With a multifaceted career spanning operational leadership, investment expertise, and regulatory advocacy, Mike seeks to bridge science, commercial & investment strategy, and policy to advance healthcare innovation.
Healthcare and Investment experience
Mike has spent several years as a VC & PE investor for a multi-billion-pound Single Family Office based in London, overseeing their direct healthcare investments in therapeutics, medtech, digital health & AI, at all stages of the VC investment lifecycle (seed – pre-IPO rounds).
Mike is Co-Founder and CEO of MICA Biosystems, a pioneering nanotech synthetic biology company now entering its clinical therapeutic phase in the UK. He is on the 2025 Forbes 30 Under 30 List (Science & Healthcare) in recognition of his achievements within healthcare. He has been Chairman of the Board at Neuro-Bio, an Alzheimer’s disease diagnostic and therapeutic company led by Baroness Susan Greenfield, where he now chairs the Commercial Advisory Board. He has also led several M&A and restructure projects in tech & AI, served as Chairman of an AI fintech company and continues to advise Family Offices and Private Equity firms.
Mike has also served in the British Army Reserve, as a Team Medic in the Royal Yeomanry, since 2017, and is on the roster of Experts for the European Commission in the verticals of Healthcare, Biotechnology & Therapeutics. His involvement in All-Party Parliamentary Groups on Dementia within His Majesty’s Government underscores his dedication to shaping healthcare policy.
Other accomplishments
With a strong foundation in biotechnology, Mike began his career conducting academic research in biomaterials and earned a Ph.D. in Bioengineering from the University of Nottingham on a fully funded scholarship from Zimmer-Biomet. This scientific background, coupled with years of operational & boardroom experience, and focus on best practice relating to human factors and change management, equips him with a well-rounded perspective on the interplay between innovation, commercialization, and patient outcomes.